Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Albumedix has appointed Jonas Skjødt Møller to lead the company as its CEO. Møller was most recently the chief operating officer of Albumedix.
Amunix Pharmaceuticals has appointed Anne Keane to the role of senior vice president of regulatory and quality. Keane was recently the vice president of regulatory at Lyell Immunopharma.
Chuck Silberstein has been named chief financial officer and head of business development of Applied Therapeutics. Most recently, Silberstein was senior vice president of corporate business development at Allergan.
Jay Ramsinghani has joined Arcutis Biotherapeutics in the role of vice president of commercial strategy and operations. Ramsinghani was most recently the senior vice president of commercial operations and strategic planning at Alastin.
William Delaney has been appointed to the position of chief scientific officer of virology at Assembly Biosciences. Delaney transitions into this role from Gilead, where he most recently served as executive director of biology.
Biotechnology Innovation Organization
Michelle McMurry-Heath has been named president and CEO of the Biotechnology Innovation Organization (BIO). McMurry-Heath comes to BIO from Johnson & Johnson, where she served as vice president of external innovation and global leader for regulatory science.
BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics has appointed Stacy Lindborg to the role of executive vice president and head of global clinical research. Before she joined BrainStorm, Lindborg was the vice president of analytics and data science at Biogen.
Cellectis has appointed Leopold Bertea to the role of senior vice president of technical operations. Bertea was general manager and site head of CellforCure prior to joining Cellectis.
Tara Heitner has taken the helm of Cyxone, where she will serve as its CEO. Prior to joining Cyxone, Heitner was CEO of Danish company ISD-Immmunotech.
Elevar Therapeutics has appointed Mark Gelder to global head of medical affairs. Gelder was most recently the chief medical officer at Pierian Biosciences.
Cameron Wolfe, associate professor of medicine at Duke University School of Medicine and leader of the school’s Coronavirus Task Force, has been appointed by Enzychem Lifesciences to spearhead the company’s U.S. efforts in developing EC-18, a potential COVID-19 therapeutic.
Sonya Montgomery has been named chief medical officer at Evox Therapeutics. Previously, Montgomery held the role of vice president and head of clinical development at Gyroscope Therapeutics.
Parisa Zamiri, former vice president and global head of clinical development and therapeutic area head for ophthalmology at Novartis, will now serve as chief medical officer at Graybug Vision.
Innoviva will now be led by Pavel Raifeld, who has taken on the position of CEO. Raifeld recently served on an investment team at Sarissa Capital Management.
Karolinska Development has found its newest chief scientific officer in John Öhd, who most recently served as chief medical officer at Modus Therapeutics.
Nima Farzan, former president and CEO of PaxVax, has been named CEO of Kinnate Biopharma.
Kronos Bio has named Zung To vice president of clinical operations. To was most recently the vice president of development operations at Jazz Pharmaceuticals.
Amie Smirthwaite has been named senior director of the global clinical practice at Maetrics. Smirthwaite previously was global head of clinical compliance at BSI Notified Body.
Yilmaz Mahshid, former chief financial officer at PledPharma, has joined Medivir as its CEO.
Joseph Leveque has assumed the role of chief medical officer at Mirati Therapeutics. Leveque joins the company from Synthorx, where he also served as chief medical officer.
Estrella Bengio has been appointed to the role of global regulatory affairs head at Nemysis. Bengio recently served as the regulatory affairs director at Abbott Nutrition.
Iya Khalil, co-founder and former chief commercial officer and executive vice president of GNS Healthcare, has been tapped by Novartis to become the global head of the organization’s artificial intelligence innovation center.
William Erhardt has been appointed to the role of chief medical officer at Oligomerix. Prior to this position, Erhardt was senior vice president and head of clinical development and operations at Pfizer.
Organon & Co.
Organon & Co., Merck’s spinoff of its women’s health, biosimilars and trusted legacy brands, has named Matthew Walsh its chief financial officer. Walsh was executive vice president and chief financial officer of Allergan before joining Organon. In addition, Rachel Stahler has been named chief information officer of Organon, joining the company from Allergan, where she served as chief information officer.
Outi Vaarala has been appointed to the role of senior vice president for research and development at the Orion Group. Before she joined Orion, Vaarala led drug discovery and development at AstraZeneca and Medimmune.
John Sundy has been appointed chief medical officer of Pandion Therapeutics. He joins the company from Gilead, where he served as senior vice president and inflammation therapeutic area head.
Jason Mills has taken the position of executive vice president of strategy at Penumbra. Mills most recently served as managing director and head of the medical technology equity research practice at Canaccord Genuity.
Paul Chaffin has been named president of the medical and pharmaceutical solutions division at Phillips-Medisize. Previously, Chaffin was senior vice president of strategic initiatives at Ecolab.
Sergei Svarovsky has been named chief scientific officer of AXIM Biotechnologies’ subsidiary Sapphire Biotech. Svarovsky, a founder of the subsidiary, was most recently director of R&D at XenBio.
Stephen Dilly has been named CEO of Sierra Oncology. Previously, Dilly was CEO of Aimmune Therapeutics.
Sutro Biopharma has announced the hiring of Craig Berman, who will assume the position of vice president of clinical development. Berman was most recently the vice president of clinical development at QED Therapeutics.
TCR² Therapeutics has named Gregg McConnell head of business development. McConnell was most recently employed by BlueRock Therapeutics as the company’s vice president and head of business development. Additionally, Viera Muzithras has been named vice president of TCR². Muzithras joins the company from Celgene, where she served as the vice president of regulatory affairs.
Ophthalmic pharma company TearClear has named Amir Shojaei its chief development officer. Shojaei most recently served as the therapeutic area head of ophthalmology at Shire/Takeda.
Theranica has announced the appointment of Dave Duff to the role of marketing and training head. Duff was formerly senior regional marketing liaison at Sunovion Pharmaceuticals. Jennifer Stanton, who most recently served as the director of national accounts at Zogenix, has also joined Theranica as the head of market access.
Herbert Harris has been named executive vice president of translational medicine of Tonix Pharmaceuticals. Harris previously served as the company’s chief medical officer from 2009 to 2011.